| Article Access Statistics|
| Viewed||2008 |
| Printed||64 |
| Emailed||0 |
| PDF Downloaded||65 |
| Comments ||[Add] |
Click on image for details.
| CLINICAL RESEARCH ARTICLES
|Year : 2021 | Volume
| Issue : 5 | Page : 364-370
Pentaglobin (immunoglobulin M-enriched immunoglobulin) as adjuvant therapy for premature and very low-birth-weight neonates with sepsis
Kawthar F Nassir1, Yasir Ibrahim AL-Saddi2, Hassan M Abbas3, Qutaiba Ahmed Al Khames Aga4, Luma Ahmed Al Khames Aga5, Ameer A Oudah6
1 Therapeutic Drug Monitoring Center, Bagdad Teaching Hospital, Mosul, Iraq
2 Department of Clinical Pharmacy, Welfare Teaching Hospital, Mosul, Iraq
3 Ministry of Health, Baghdad, Department of Clinical Pharmacy, Mosul, Iraq
4 Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, Jordan
5 Ministry of Health, Nineveh Health Directorate, Department of Gynecology, Mosul, Iraq
6 Department of Clinical Pharmacy, Bagdad Teaching Hospital, Medical City, Mosul, Iraq
OBJECTIVES: The purpose of this research was to determine the effectiveness of Pentaglobin® as adjuvant therapy in the treatment of sepsis in preterm newborns.
MATERIALS AND METHODS: It was a prospective, observational, randomized study for 272 premature neonates and very low birth weight (VLBW) that were diagnosed with sepsis carried at neonatal intensive care units. The patients randomized into control group who received standard sepsis antibiotic treatments, and an intervention group who received Pentaglobin® 5 ml/kg daily for 3 consecutive days as an adjunct therapy to a standard sepsis antibiotic treatment.
RESULTS: Multiple organisms that isolated from culture specimens were Gram-negative bacteria, Gram-positive, and candida (56.25%, 42.28%, and 1.47%, respectively). The disease duration was distinctively longer in patients who were treated by the standard antibiotic protocol (mean ± standard deviation [SD]: 30.76 ± 3.97, odds ratio [OR]: 30.76, 95% confidence interval [CI]: 30.051, 31.473) comparing to the patients who received Pentaglobin adjuvant therapy (mean ± SD: 26.48 ± 5.55, OR: 26.48, 95% CI: 25.489, 27.477) (P < 0.000). Patients treated by standard antibiotic protocol were associated to a substantially increased risk of death (11.76%, hazard ratio 4.400, 95% CI: 1.432, 13.529, P = 0.009).
CONCLUSION: Neonatal sepsis is more common in premature and VLBW newborns, and Pentaglobin® management of newborn nosocomial sepsis might be used in addition to other therapies.
Dr. Qutaiba Ahmed Al Khames Aga
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*